 Passage Bio, Inc. PASG, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced the appointment of Athena Countouriotis to its board of directors. We are immensely excited to have Athena join our board of directors, said Dr. Bruce Goldsmith, chief executive officer of Passage Bio. Her public company operations leadership, deep clinical development expertise and salient gene therapy experience will provide tremendous support to Passage Bio as we move forward as a newly publicly traded company and advance our lead programs into clinical development starting in the second half of 2020. 